WEKO3
アイテム
{"_buckets": {"deposit": "6b96706f-4381-4abe-a30e-954cfa74f391"}, "_deposit": {"created_by": 30, "id": "1681", "owners": [30], "pid": {"revision_id": 0, "type": "depid", "value": "1681"}, "status": "published"}, "_oai": {"id": "oai:oist.repo.nii.ac.jp:00001681", "sets": ["91"]}, "author_link": ["10096", "10092", "10094", "10091", "10097", "10093", "10098", "10090", "10099", "10095"], "item_10001_biblio_info_7": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "60", "bibliographicPageStart": "45", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{}, {"bibliographic_title": "Behavioural Pharmacology", "bibliographic_titleLang": "en"}]}]}, "item_10001_creator_3": {"attribute_name": "Author", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ando, Kiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "10090", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "10091", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hikishima, Keigo"}], "nameIdentifiers": [{"nameIdentifier": "10092", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Komaki, Yuji"}], "nameIdentifiers": [{"nameIdentifier": "10093", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawai, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "10094", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue, Ryo"}], "nameIdentifiers": [{"nameIdentifier": "10095", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishime, Chiyoko"}], "nameIdentifiers": [{"nameIdentifier": "10096", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishinaka, Eiko"}], "nameIdentifiers": [{"nameIdentifier": "10097", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Urano, Koji"}], "nameIdentifiers": [{"nameIdentifier": "10098", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okano, Hideyuki"}], "nameIdentifiers": [{"nameIdentifier": "10099", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_description_5": {"attribute_name": "Abstract", "attribute_value_mlt": [{"subitem_description": "Baseline locomotion and behavioral traits in the common marmoset Parkinson\u0027s disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson\u0027s disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_publisher": "Wolters Kluwer Health, Inc."}]}, "item_10001_relation_13": {"attribute_name": "PubMedNo.", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "info:pmid/31625972", "subitem_relation_type_select": "PMID"}}]}, "item_10001_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.1097/FBP.0000000000000509", "subitem_relation_type_select": "DOI"}}]}, "item_10001_relation_17": {"attribute_name": "Related site", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://journals.lww.com/behaviouralpharm/FullText/2020/02000/Measurement_of_baseline_locomotion_and_other.6.aspx", "subitem_relation_type_select": "URI"}}]}, "item_10001_rights_15": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_rights": "© 2019 The Author(s)"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0955-8810", "subitem_source_identifier_type": "ISSN"}, {"subitem_source_identifier": "1473-5849", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "Author\u0027s flag", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-08-19"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Ando-2020-Measurement of baseline locomotion a.pdf", "filesize": [{"value": "915.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (https://creativecommons.org/licenses/by-nc-nd/4.0/)", "licensetype": "license_free", "mimetype": "application/pdf", "size": 915100.0, "url": {"label": "Ando-2020-Measurement of baseline locomotion a", "url": "https://oist.repo.nii.ac.jp/record/1681/files/Ando-2020-Measurement of baseline locomotion a.pdf"}, "version_id": "e767de84-96a5-4cac-9048-c4707116a9dd"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "1-methyl-4-phenyl-1", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "2", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "3", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "6-tetrahydropyridine", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "circling", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "locomotor activity", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "marmoset", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MRI", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Parkinson\u0027s disease", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinsonʼs disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinsonʼs disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "30", "path": ["91"], "permalink_uri": "https://oist.repo.nii.ac.jp/records/1681", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-08-19"}, "publish_date": "2020-08-19", "publish_status": "0", "recid": "1681", "relation": {}, "relation_version_is_last": true, "title": ["Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinsonʼs disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"], "weko_shared_id": 30}
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinsonʼs disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
https://oist.repo.nii.ac.jp/records/1681
https://oist.repo.nii.ac.jp/records/16813e9d3eb8-34d8-4a8b-b702-404bfb337727
名前 / ファイル | ライセンス | アクション |
---|---|---|
Ando-2020-Measurement of baseline locomotion a (915.1 kB)
|
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (https://creativecommons.org/licenses/by-nc-nd/4.0/)
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-08-19 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinsonʼs disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | 1-methyl-4-phenyl-1 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | 2 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | 3 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | 6-tetrahydropyridine | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | circling | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | locomotor activity | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | marmoset | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | MRI | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Parkinson's disease | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者(英) |
Ando, Kiyoshi
× Ando, Kiyoshi× Inoue, Takashi× Hikishima, Keigo× Komaki, Yuji× Kawai, Kenji× Inoue, Ryo× Nishime, Chiyoko× Nishinaka, Eiko× Urano, Koji× Okano, Hideyuki |
|||||
書誌情報 |
en : Behavioural Pharmacology 巻 31, 号 1, p. 45-60, 発行日 2020-02 |
|||||
抄録 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson's disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations. | |||||
出版者 | ||||||
出版者 | Wolters Kluwer Health, Inc. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0955-8810 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1473-5849 | |||||
PubMed番号 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | info:pmid/31625972 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | info:doi/10.1097/FBP.0000000000000509 | |||||
権利 | ||||||
権利情報 | © 2019 The Author(s) | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://journals.lww.com/behaviouralpharm/FullText/2020/02000/Measurement_of_baseline_locomotion_and_other.6.aspx | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |